SARS_CoV_2 mutation literature information.


  Mutations that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway.
 PMID: 35093235       2022       Cell reports
Result: A number of these variants have RBD mutations such as L452R, E484K, and/or N501Y, which are thought to promote human ACE2 binding.
Result: B.1.1.7/E484K, Iota/B.1.526 + E484K (first associated with infections in New York), Eta/B.1.525 (a variant with associations with West Africa), and L452R (in multiple variants of concern, including Epsilon/B.1.427/B.1.429, first associated with infections in California, and Delta/B.1.617.2, which is currently replacing all other SARS-CoV-2 lineages globally) all allowed pseudovirus to use ferret ACE2 for cell
Figure: Alpha also known as B.1.1.7; Beta also known as B.1.351; Gamma also known as P.1; Eta also known as B.1.525; Iota also known as B.1.526 + E484K.


  Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern.
 PMID: 35093484       2022       The Journal of allergy and clinical immunology
Abstract: Interestingly, all 3 vaccines could neutralize all tested variants of concern in addition to WT virus, but in some individuals, only low or no neutralization, especially against Alpha-E484K and the Delta variant, was detected.
Abstract: We also determined the neutralization ability against SARS-CoV-2 WT and B.1.1.7 (Alpha), B1.1.7 E484K (Alpha-E484K), B.1.351 (Beta), and B.1.617.2 (Delta) variants.


  Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model.
 PMID: 35101265       2022       Vaccine
Table: E484K
Discussion: The Beta and Gamma variants are the most resistant to monoclonal antibodies (mAbs) and convalescent plasma from SARS CoV-2-infected individuals, and the resistance profiles correspond to several deletions in the N-terminal domain and the K417N/T, E484K/Q, and N501Y mutations in the RBD of SARS-CoV-2 Spike protein.
Discussion: The E484 position was identified as a dominant residue for escape from neutralizing activity by sera from COVID-19 convalescent patients with the E484K mutation in the SARS-CoV-2 Beta variant as the key factor responsible for the reduced neutralization potency of c


  Mutations in the receptor-binding domain of human SARS CoV-2 spike protein increases its affinity to bind human ACE-2 receptor.
 PMID: 35109768       2022       Journal of biomolecular structure & dynamics
Abstract: Here, we use the crystal structure of the RBD in complex with ACE-2 available in the public domain and analyse the 250 ns molecular dynamics (MD) simulations of wild-type and mutants; K417N, K417T, N440K, N501Y, L452R, T478K, E484K and S494P.


  Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients.
 PMID: 35113647       2022       Science immunology
Method: The beta variant contained the following spike changes: L18F, D80A, D215G, del241-243, K417N, E484K, N501Y, D614G, and A701V.


  Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display.
 PMID: 35114110       2022       Cell reports
Abstract: Further, we engineer a potent ACE2-blocking nAb to sustain binding to S RBD with the E484K and L452R substitutions found in multiple SARS-CoV-2 variants.
Result: E484K:an escape mutant found in many different variants, including B.1.351 and A.VOI.V2 :did, however, reduce the binding affinity of N-612-017 by 6- to 10-fold (Figures 6A and 6B).
Result: Generation of E484K- and L452R-resistant N-612-017.


  Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine.
 PMID: 35118474       2022       bioRxiv
Method: D614G spike mutation: D614G; Alpha (B.1.1.7) spike mutations: Delta69-70, Delta144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H; Beta (B.1.351) spike mutations: L18F, D80A, D215G, Delta242-244, R246I, K417N, E484K, N501Y, D614G, A701V; Delta (B.1.61


  SARS-CoV-2 Variants Associated with Vaccine Breakthrough in the Delaware Valley through Summer 2021.
 PMID: 35130727       2022       mBio
Introduction: Some of the substitutions in these variants have been detected arising independently on multiple genetic backgrounds, such as the spike substitutions N501Y, E484K or the 69-70 deletion, supporting a model of convergent evolution.
Result: Two other closely studied spike substitutions, E484K and L452R, were not notably enriched among vaccine breakthrough cases, and the D253G substitution was modestly depleted.


  Emerging Vaccine-Breakthrough SARS-CoV-2 Variants.
 PMID: 35133792       2022       ACS infectious diseases
Introduction: By analyzing the frequency, binding free energy (BFE) changes, and antibody disruption counts of RBD comutations, we reveal that nine RBD comutation sets, namely [L452R, T478K], [L452Q, F490S], [E484K, N501Y], [F490S, N501Y], [S494P, N501Y], [K417T, E484K, N501Y], [K417N, L452R, T478K], [K417N,


  Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants.
 PMID: 35136050       2022       Nature communications
Introduction: The S protein E484Q mutation in the Kappa variant was similarly found in the Beta (B.1.351) and Gamma (P.1) lineages, where residue 484 is mutated to lysine (E484K).
Result: We have previously demonstrated the sensitivity of ab8 and S2M11 to the E484K mutation, wherein both antibodies were fully escaped.
Figure: The K484 surface potential was generated using the previously reported D614G + N501Y + E484K focus-refined atomic model.



Browser Board

 Co-occurred Entities




   Filtrator